Patents Examined by Sun Jae Loewe
  • Method for preparing a material formed from arborescent-branched molecules comprising associative groups
    Patent number: 8530671
    Abstract: The present invention relates to a method of preparing a material formed from arborescent-branched molecules comprising associative groups that includes the following successive steps: (a) the reaction of at least one at least trifunctional compound (A) bearing first and second functional groups with at least one bifunctional compound (B), the functional groups of which are capable of reacting with the first functional groups of the compound (A); and (b) the reaction of the compound(s) obtained in step (a) with at least one compound (C) bearing, on the one hand, at least one reactive group capable of reacting with the second functional groups of (A) and, on the other hand, at least one given associative group.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 10, 2013
    Assignees: Arkema France, Centre National de la Recherche Scientifique CNRS
    Inventors: François-Genes Tournilhac, Manuel Hidalgo, Ludwik Leibler
  • Pyripyropene derivatives having an ACAT2-inhibiting activity
    Patent number: 8519128
    Abstract: The present invention is a compound having the general formula (I), (II), or (III) or a pharmacologically acceptable salt, solvate, or hydrate thereof, and a pharmaceutical composition containing such a compound, or its pharmacologically acceptable ester, or other pharmacologically acceptable derivative thereof as an active ingredient. The compound has an excellent ACAT 2-inhibiting activity by a mechanism different from that of a statin drug and is useful as a therapeutic or prophylactic agent for obesity, adiposis, hyperlipidemia, hypercholesterolemia, disorder of lipid metabolism, and arteriosclerosis, as well as obesity-derived hyperlipidemia, hypercholesterolemia, disorder of lipid metabolism, arteriosclerosis, and hypertension.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: August 27, 2013
    Assignee: The Kitasato Institute
    Inventors: Hiroshi Tomoda, Tohru Nagamitsu, Satoshi Omura
  • ABT-263 crystalline forms
    Patent number: 8513243
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 20, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • Homocysteine synthase inhibitor
    Patent number: 8513235
    Abstract: The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: August 20, 2013
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Akira Nakao, Hiroko Suzuki, Ryo Tatsumi, Maki Seki, Minoru Tanaka, Tomofumi Setsuta, Hiroshi Iwasaki
  • Anthelmintic agents and their use
    Patent number: 8507474
    Abstract: This invention is directed to compounds of the formula (I) and salts therefore that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds of this invention, pharmaceutical compositions and kits comprising the compounds of this invention, uses of the compounds of this invention to make medicaments, and treatments comprising the administration of the compounds of this invention to animals in need of the treatments.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: August 13, 2013
    Assignee: Intervet International B.V.
    Inventors: Christophe Pierre Alain Chassaing, Thorsten Meyer
  • Isoxazole compounds as inhibitors of heat shock proteins
    Patent number: 8507480
    Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: August 13, 2013
    Assignees: Vernalis (R&D) Limited, Cancer Research Technology Limited, The Institute of Cancer Research
    Inventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
  • Phosphoramidate alkylator prodrugs
    Patent number: 8507464
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: August 13, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Cinnamic acid-based oligomers and uses thereof
    Patent number: 8491872
    Abstract: Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. ?-O4 and ?-5 trimers and tetramers) are used as anticoagulants.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: July 23, 2013
    Assignee: Virginia Commonwealth University
    Inventors: Umesh R. Desai, Brian L. Henry, Aiye Liang, Jay Thakkar, John B. Mangrum, Ivo Torres Filho, Bruce D. Spiess, Masahiro Sakagami, Bhawana Saluja
  • 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 8492387
    Abstract: The present invention is directed to 2-aminoimidazole compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: July 23, 2013
    Assignee: Merck, Sharp & Dohme, Corp.
    Inventors: Ivory D. Hills, Craig A. Coburn, Samuel L. Graham, Keith P. Moore, Philippe G. Nantermet, Hemaka A. Rajapakse, Shawn J. Stachel, Hong Zhu
  • Arylalkylamine compound and process for preparing the same
    Patent number: 8492111
    Abstract: The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: July 23, 2013
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Hiroshi Miyazaki, Junko Tsubakimoto, Kosuke Yasuda, Iwao Takamuro, Osamu Sakural, Tetsuya Yanagida, Yataka Hisada
  • Viral polymerase inhibitors
    Patent number: 8476257
    Abstract: Compounds of formula I: wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: July 2, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Pierre L. Beaulieu, Pasquale Forgione, Alexandre Gagnon, Cedrickx Godbout, Marc-Andre Joly, Montse Llinas-Brunet, Julie Naud, Martin Poirier, Jean Rancourt
  • Electroactive materials
    Patent number: 8471251
    Abstract: There is provided an electroactive material having Formula I wherein: Q is the same or different at each occurrence and can be O, S, Se, Te, NR, SO, SO2, or SiR3; R is the same or different at each occurrence and can be hydrogen, alkyl, aryl, alkenyl, or alkynyl; R1 through R8 are the same or different and can be hydrogen, alkyl, aryl, halogen, hydroxyl, aryloxy, alkoxy, alkenyl, alkynyl, amino, alkylthio, phosphino, silyl, —COR, —COOR, —PO3R2, —OPO3R2, or CN.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: June 25, 2013
    Assignee: E.I. du Pont de Nemours and Company
    Inventor: Hong Meng
  • Cyclic guanidine ionic liquid
    Patent number: 8450478
    Abstract: Disclosed is an ionic liquid which is stable over a wide potential range and exhibits a high ionic conductivity. The ionic liquid comprises a cyclic guanidine salt represented by the following formula (1): wherein R1 and R2 each is independently an alkyl group or an alkoxyalkyl group, X is a methylene group, an oxygen atom, a sulfur atom, or R3N; R3 is an alkyl group, an alkoxyalkyl group, or an acyl group; l, m, and n each is an integer in the range of 1-6; Y? is a monovalent anion such as (R4SO2)2N?, R4SO3?, R4COO?, BF4?, PF6?, NO3?, (CN)2N?, (CHO)2N?, NCS?, R4OSO3?, R4SO2S?, and a halogen ion. The ionic liquid is useful for a variety of electrolytes, particularly for electrolytes of electrochemical cells.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: May 28, 2013
    Assignee: Nippon Steel & Sumikin Chemical Co., Ltd.
    Inventors: Atsushi Kawada, Aya Tashiro, Toshihiro Kumagai
  • Isoxazole compounds as inhibitors of heat shock proteins
    Patent number: 8450310
    Abstract: Isoxazoles of formula (A) or (B) wherein R1 is a group of formula (IB) The isoxazoles are inhibitors of HSP90 activity, and useful for the treatment of, for example, cancers.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 28, 2013
    Assignees: Vernalis (R&D) Limited, Cancer Research Technology Ltd., The Institute of Cancer Research
    Inventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
  • Modified lysine-mimetic compounds
    Patent number: 8431540
    Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: April 30, 2013
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Ketil Jørgen Haugan, John A. Butera, James K. Hennan, Edward H. Kerns, Evgueni Lvovich Piatnitski
  • Dicycloazaalkane derivatives, preparation processes and medical uses thereof
    Patent number: 8415349
    Abstract: The invention provides derivatives of azabicyclo alkane having formula (ID), and the method for making them, wherein each substitute in formula (ID) is same as defined in the description.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 9, 2013
    Assignee: Jiangsu Hansoh Pharmaceuticals Co., Ltd.
    Inventors: Peng Cho Tang, Zhigang Lin, Hejun Lü, Fuqiang Zhao, Li Li, Fanglong Yang, Jianghong Fu, Lin Wang, Guangyuan Shen, Dongliang Guan
  • 5-membered heterocycle-based P38 kinase inhibitors
    Patent number: 8410160
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38?, and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 2, 2013
    Assignee: Novartis AG
    Inventors: Olga M. Fryszman, Hengyuan Lang, Jiong Lan, Edcon Chang, Yunfeng Fang
  • Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
    Patent number: 8410267
    Abstract: The present invention relates to a method for regioselectively reducing the maleimide compounds of formula (I). The invention also relates to C7 hydroxy lactam regioisomers of formula (II) obtainable by this method and their use for the preparation of lactams of formula (III) which are particularly useful as intermediate for the synthesis of fused pyrrolocarbazoles.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: April 2, 2013
    Assignee: Teva Sante
    Inventor: Laurence Prat-Lacondemine
  • Substituted isoindoline-1,3-dione derivatives
    Patent number: 8404737
    Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: March 26, 2013
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Julie F. Liu
  • Process for preparing azabicyclic compounds
    Patent number: 8404865
    Abstract: The present invention relates to a process for preparing azabicyclic compounds that are useful intermediates for synthesizing pharmaceutical compounds or salts thereof.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: March 26, 2013
    Assignee: Vertex Pharmaceuticals
    Inventors: Narendra Bhalchandra Ambhaikar, Brian Richard Bear, Lev T. D. Fanning, Robert Hughes, Benjamin Littler